Edronax


Also found in: Dictionary, Medical, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for Edronax

an antidepressant drug that blocks the reuptake of norepinephrine

References in periodicals archive ?
The British Medical Journal (BMJ) review concludes Edronax is "ineffective and potentially harmful".
Edronax belongs to a class of compounds called selective noradrenaline reuptake inhibitors, which have been shown to increase the availability of a neurochemical known as noradrenaline.
In Phase III clinical trials with more than 1,500 adult and elderly patients suffering from major depression, Edronax was shown to be a safe and effective antidepressant in both short and long-term treatment of outpatients and hospitalized patients.
market clearance of Edronax for depression First Quarter First Quarter Financial summary 1997 1996 % change Sales $1.
The company told analysts that during 1997 it has received first approvals of five new chemical entities: Detrusitol, Edronax, Mirapex for Parkinson's disease, Rescriptor for HIV infection and Vistide, a treatment of cytomegalovirus infections of the eye.
This will enhance the company's ability to launch new primary care products such as Detrusitol and Edronax and to attract new licensing opportunities.
In general, side effects associated with Edronax therapy were of mild to moderate severity, appeared early and tended to diminish with time.
The company markets Mirapex for Parkinson's disease and Edronax for depression in various markets worldwide.
Reboxetine is marketed outside the United States as Edronax and Norebox tablets, and is available in the United Kingdom, Ireland, Italy, Finland, Germany, Sweden, Belgium, Denmark, Spain and Austria.
IQWiG: Institute for Quality and Efficiency in Health Care, Gemeinsame Bundesausschuss (GBA), Federal Joint Committee, evidence-based decisions, Novo Nordisk's Novorapid, Eli Lilly's Humalog/ Liprolog, Sanofi -Aventis's Apidra, insulin analogues, value added, Pfizer's Exubera, Sanofi -Aventis's Lantus, Novo Nordisk's Levemir, cancer risk, Pfizer's Edronax, GlaxoSmithKline's bupropion, Essex Pharma's mirtazapine.